In short, Xiidra and Miebo may be beginning to justify ... may soon be subject to generic drug competition as its patents expire. This will almost certainly lead to a 15 — 25% per annum drop ...

But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ageing Restasis potentially facing generic competition, there’s a lot to play for ...

INR:9726. play india Novartis withdraws Xiidra EU marketing application. Is Takeda's $1.9 billion milestone payment in jeopardy? Boehringer Ingelheim and Click Therape ...